Allbirds Rebrands As NewBird AI After $39 Million Asset Sale

by THEFUTURE.TEAM

April 16, 2026

A Bold Strategic Pivot

Former Allbirds entity sold its footwear brand and related assets for $39 million and rebranded as NewBird AI. The company now positions itself as a GPU-as-a-Service and AI cloud infrastructure provider. Rebranding was announced through the investor relations platform, marking a shift toward AI-focused operations.

Significant Institutional Backing

NewBird AI secured $50 million in funding from an institutional investor through a convertible financing facility. Capital will support infrastructure development and expansion into AI services. Funding reflects continued investor interest in AI compute and infrastructure.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Learning From The Past

Transition from a consumer brand to an AI infrastructure provider represents a major change in business model. Similar rebranding cases have previously attracted market attention, including Long Island Iced Tea’s shift to Long Blockchain in 2017, which led to a temporary increase in share price. That case later led to delisting, highlighting the risks associated with rapid repositioning. NewBird AI continues to operate under the Nasdaq-listed ticker “BIRD”.

Future Plans And Market Outlook

Shareholder approval is expected at a meeting scheduled for May 18. Planned actions include a dividend distribution in the third quarter. American Exchange Group will manage the Allbirds brand and continue serving customers. NewBird AI plans to allocate capital to GPU acquisitions and to expand its services through partnerships, mergers, and acquisitions.

The Future Forbes Realty Global Properties

Colossal Biosciences Seeks Funding At Up To $30 Billion Valuation

by THEFUTURE.TEAM

July 22, 2026

Colossal Biosciences, the biotechnology startup known for its efforts to revive extinct species including the woolly mammoth and dire wolf, is in talks to raise funding at a valuation of $20 billion to $30 billion, according to Axios.

The company was last valued at $10.2 billion in a January funding round. It has since begun generating revenue, Axios reported, although neither the size of the new financing nor its potential investors have been disclosed.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Business Extends Beyond De-Extinction

While Colossal has attracted global attention for its de-extinction projects, the company is also building a broader biotechnology business around the tools developed through that research.

Co-founder and Chief Executive Ben Lamm has said Colossal expects revenue from three areas: conservation technologies, new businesses created from its research and future commercial applications of technologies developed alongside its de-extinction programme.

Expanding Commercial Portfolio

Colossal has already supplied conservation technology to the U.S. government and the United Arab Emirates, which recently invested $60 million in the company, according to Wired.

Its research has also led to the creation of several startups, including plastics recycling company Breaking, computational biology platform Form Bio, which raised $30 million, and AI-driven biology company Astromech, which was valued at $2 billion in March.

Research Continues To Expand

Operating from a 55,000-square-foot facility in Dallas, Colossal continues to broaden its research portfolio.

In April, the company added the bluebuck antelope as its sixth de-extinction target. More recently, the Colossal Foundation partnered with the University of Tasmania to develop vaccines and gene-editing approaches aimed at protecting Tasmanian devils from a contagious facial cancer.

Lamm has also said the company plans to spin out its artificial womb technology, which could eventually have applications in fertility treatment. Speaking to Rolling Stone in May, he said the technology could be ready next year.

Investor Interest In Deep Tech

The fundraising discussions come as investors increase spending on sectors such as biotechnology, longevity and other deep-tech fields.

Lamm has also said Colossal could eventually generate revenue from biodiversity credits if restored species are successfully reintroduced into their natural habitats, creating another potential commercial opportunity.

Breaking news